Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Search results

Search results page

Articles (9)

Journals (0)

1-9 of 9 results for PALOMA 2

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

Open access

Research article

First published 2023

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching [...]

Therapeutic Advances in Medical Oncology

Select article: Axillary chest wall solid-papillary carcinoma: A case report on presentation and management

Open access

Case report

First published January, 2023

Axillary chest wall solid-papillary carcinoma: A case report on presentation and management

Harper E. Niver, Priscilla Strom

Rare Tumors

Select article: Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Open access

Editorial

First published 2018

Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Lorenzo Rossi, Amelia McCartney, Emanuela Risi [...]

Therapeutic Advances in Medical Oncology

Select article: Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy

Open access

Research article

First published 2019

Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy

Tam Binh V Bui, Desirée MT Burgers, Mariette J Agterof [...]

Breast Cancer: Basic and Clinical Research

Select article: Palbociclib

Restricted access

Review article

First published November, 2015

Palbociclib

Neha S. Mangini, Robert Wesolowski, Bhuvaneswari Ramaswamy [...]

Annals of Pharmacotherapy

Select article: Updates on managing advanced breast cancer with palbociclib combination therapy

Open access

Review article

First published 2018

Updates on managing advanced breast cancer with palbociclib combination therapy

Teresa M. McShane, Thomas A. Wolfe, Joanne C. Ryan

Therapeutic Advances in Medical Oncology

Select article: Book review: PALOMA GAY Y BLASCO and HUON WARDLE,How to Read Ethnography. London: Routledge,2007,214 pp. (index included). ISBN 0 415 32866 7 (hbk) £60.00,0 415 32867 5 (pbk),£18.99,0 203 39096 2 (ebk)

Restricted access

Review article

First published April, 2008

Book review: PALOMA GAY Y BLASCO and HUON WARDLE,How to Read Ethnography. London: Routledge,2007,214 pp. (index included). ISBN 0 415 32866 7 (hbk) £60.00,0 415 32867 5 (pbk),£18.99,0 203 39096 2 (ebk)

Paul Atkinson

Qualitative Research

Select article: The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Restricted access

Article commentary

First published September, 2020

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Select article: Software Reviews : The PROPI Authoring System Reviewer: Dennis H. O'Neil,Palomar College Publisher: ASYS Computer Systems,io4 Viewcrest,Bellingham,wA 98225;206-734-2553 Year of Publication: 1989 Versions: PROPI 3.0,AFL (Advanced Feature Library) 4.3,and Pc-Pi- lot 4.4 Materials: Three 720K disks,307-page PRopi manual,26 pages of programming tips,184-page Pc-Pilot manual Price: "Complete system" prices are $2,600 for an individual license and $8,00o for a site license;educational prices are $1,)00 individual and $3,700 site license. "Basic system" prices (not including pc-Pi- lot) are $2,100 for individual and $6,00o for site;educational prices are $90o for individual and $2,100 for site. Upgrades are $150 for PROPI,$50 for AFL,and $50 for pc-Pilot (from version 4.0 or higher). Machine Specificity: IBM PC/XT/AT or ps/i/2 and compatibles System Requirements: 512K RAM (640K recommended);hard disk drive;DOS 3.1 or higher;CGA,EGA,MCGA,or vGA graphics capability;Microsoft-compatible mouse recommended Effectiveness: Very good User-Friendliness: Good Documentation: Good

Restricted access

Review article

First published December, 1991

Software Reviews : The PROPI Authoring System Reviewer: Dennis H. O'Neil,Palomar College Publisher: ASYS Computer Systems,io4 Viewcrest,Bellingham,wA 98225;206-734-2553 Year of Publication: 1989 Versions: PROPI 3.0,AFL (Advanced Feature Library) 4.3,and Pc-Pi- lot 4.4 Materials: Three 720K disks,307-page PRopi manual,26 pages of programming tips,184-page Pc-Pilot manual Price: "Complete system" prices are $2,600 for an individual license and $8,00o for a site license;educational prices are $1,)00 individual and $3,700 site license. "Basic system" prices (not including pc-Pi- lot) are $2,100 for individual and $6,00o for site;educational prices are $90o for individual and $2,100 for site. Upgrades are $150 for PROPI,$50 for AFL,and $50 for pc-Pilot (from version 4.0 or higher). Machine Specificity: IBM PC/XT/AT or ps/i/2 and compatibles System Requirements: 512K RAM (640K recommended);hard disk drive;DOS 3.1 or higher;CGA,EGA,MCGA,or vGA graphics capability;Microsoft-compatible mouse recommended Effectiveness: Very good User-Friendliness: Good Documentation: Good

Social Science Computer Review

1
10 / page

Filter Results

Article type

Publication date

Subjects

Access